問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 1,704

    Total Beds

  • 806

    Total Doctors

  • ctc@ms.kmuh.org.tw
  • Yu-Sam Lin
  • 886-7-3121101#6643
  • 807Kaohsiung CityKaohsiung SanminNo.100, Tzyou 1st Rd., Sanmin Dist.,Sanmin,Kaohsiung City 807

Recruiting Trial

549Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1256Cases

2025-10-01 - 2029-12-31

Active
A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Condition/Disease

    Squamous Cell Carcinoma of Head and Neck

  • Test Drug

    Injectable drugs Subcutaneous injections Injectable drugs Injectable drugs Injectable drugs

Participate Sites
7Sites

Recruiting7Sites

2025-10-01 - 2028-12-31

Phase I/II

Active
An Open-label, Multicenter, Phase 1/2 Study Exploring the Safety and Efficacy of ABT-301 in Combination With Tislelizumab and Bevacizumab in Participants With Proficient Mismatch Repair (pMMR)/Non-Microsatellite Instability-High (Non-MSI-H) Locally Advanced or Metastatic Colorectal Cancer (mCRC)

  • Condition/Disease

    Colorectal Cancer (Diagnosis)

  • Test Drug

    Capsules Intravenous Infusion Intravenous Infusion Capsules

Participate Sites
7Sites

Recruiting7Sites

2025-10-31 - 2029-06-26

Not yet recruiting
A phase 2b, randomized, double-blind, placebo-controlled, parallel-group trial was conducted to evaluate the efficacy and safety of Verekitug (UPB-101) in participants with moderate to severe chronic obstructive pulmonary disease (COPD).

  • Condition/Disease

    Moderate to severe chronic obstructive pulmonary disease (COPD)

  • Test Drug

    UPB-101

Participate Sites
8Sites

Not yet recruiting8Sites

2025-11-01 - 2030-12-31

Phase II

Active
A phase 2b/3, randomized, double-blind, placebo-controlled, multicenter trial was conducted to investigate the efficacy and safety of lunsekimig in adult subjects with poorly controlled chronic obstructive pulmonary disease (COPD) of the eosinophilic leukocytosis phenotype.

  • Condition/Disease

    The efficacy of lunsekimig was assessed by measuring the annualized incidence of moderate to severe COPD exacerbations.

  • Test Drug

    Lunsekimig/ SAR443765

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

2025-11-11 - 2030-12-31

Phase II/III

Active
A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (PF-06946860) Compared With Placebo Both With Background First-Line Chemotherapy in Adult Participants With Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma

  • Condition/Disease

    Cachexia

  • Test Drug

    Injectable

Participate Sites
5Sites

Not yet recruiting5Sites

2025-11-14 - 2031-03-30

Active
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

  • Condition/Disease

    Heart Failure With Preserved Ejection Fraction

  • Test Drug

    subcutaneous injection

Participate Sites
6Sites

Not yet recruiting6Sites

2025-12-28 - 2031-12-31

Phase III

Not yet recruiting
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (WHO Group 3)

  • Condition/Disease

    Pulmonary Hypertension Due to Lung Disease (Disorder)

  • Test Drug

    Inhalation suspensions

Participate Sites
5Sites

Recruiting5Sites

2025-12-01 - 2032-08-02

Others

Active
AFFIRM: A randomized, double-blind, placebo-controlled trial designed to evaluate the effect of Seladelpar on clinical outcomes in patients with primary biliary cholangitis (PBC) and compensated cirrhosis.

  • Condition/Disease

    1. EFS should be assessed by the time elapsed from the start of treatment to the first occurrence of any of the following adjudicated events at week 156: a. death from any cause b. liver transplantation c. MELD score ≥ 15 d. ascites requiring treatment e. hospitalization for any of the following criterion events: i. esophageal or gastric variceal bleeding ii. hepatic encephalopathy (defined as West Haven score ≥ 2) iii. spontaneous bacterial peritonitis confirmed by diagnostic paracentesis based on WBC count, differential, and/or positive growth in aerobic and/or anaerobic blood cultures. Further details regarding clinical events requiring adjudication should be provided. 2. Assessment of treatment-induced adverse events (TEAEs); biochemical and hematological laboratory evaluation.

  • Test Drug

    Seladelpar

Participate Sites
7Sites

Not yet recruiting7Sites

2025-12-11 - 2031-06-30

Phase III

Not yet recruiting
A phase 3, randomized, double-blind, placebo-controlled trial was conducted to evaluate the efficacy and safety of GB-0895 adjunctive therapy in adults and adolescents with severe, poorly controlled asthma.

  • Condition/Disease

    Adults and adolescents with severely uncontrolled asthma

  • Test Drug

    GB-0895

Participate Sites
6Sites

Recruiting6Sites

2019-12-01 - 2030-05-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
17Sites

Not yet recruiting4Sites

Recruiting13Sites

1 2 3 4 5 126
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB